Answers are grounded in this paper and cite their sources.
Cell therapies and tissue-engineered products that contain living cells are potentially some of the most exciting of the novel therapeutic products currently under development. These products, however, present a number of important safety issues, particularly with respect to the transmission of human viruses. In addition, the short shelf life of these products precludes the normally extensive characterization performed on other biotherapeutic products. Careful examination of the risks and extensive testing of the raw materials have been used in place of product testing to ensure safety.
No takes yet. Share an insight, caveat, or question.
Daniel N. Galbraith (2004) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: